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N
atural compounds isolated from marine organ-
isms have been found to be a very rich source
of bioactive molecules. Reported biological ef-
fects of these compounds include anti-tumor, anti-
inﬂammatory, and anti-viral activities, as well as immu-
nomodulatory and analgesic properties (1, 2). Among
marine organisms, sponges have been proven to be ex-
cellent producers of secondary metabolites that exhibit
biological activities. More than 5,300 compounds have
been isolated from sponges with around 200 new mol-
ecules reported each year (3). Bromopyrrole alkaloids
constitute a family of exclusively marine alkaloids and
represent a fascinating example of the large variety of
compounds formed by marine sponges (4). About 140
derivatives, with different structures and biological ac-
tivities, have been isolated from more than 20 different
sponges of various genera, most of them belonging to
Agelasidae, Axinellidae, and Halichondridae families
(5).
Oneofthemembersofthisfamilyissceptrin.Firstiso-
lated by Faulkner, Clardy, and co-workers (6) from
Agelas sceptrum sponge in 1981, sceptrin is of consid-
erable pharmaceutical interest because it exhibits a
broad array of biological activities, including anti-
bacterial/anti-fungal, anti-muscarinic and anti-
histaminic (7−10). It has been reported that sceptrin is
the most potent nonpeptidic inhibitor of somatostatin
(11),implyingitspotentialasatreatmentforcysticﬁbro-
sis and Alzheimer’s disease. Encouragingly, sceptrin
was also found to be noncytotoxic to monkey liver cells
(12) and to mice at 50 mg kg1 (6). Interestingly, Ro-
driguezandco-workers(13)haverecentlydemonstrated
the interaction of sceptrin with the bacterial MreB pro-
tein. MreB protein is considered to be the actin homo-
logue in bacteria, raising the possibility that sceptrin
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ABSTRACT Sceptrin, a natural compound produced by various marine sponges,
was tested for its effect on cell motility. We report for the ﬁrst time that sceptrin in-
hibits cell motility in several cancer cell lines. The compound shows no toxicity at
concentrations that are double the amount of sceptrin required for maximal inhibi-
tory effect. Both random and factor-induced migration were impaired, suggesting
that sceptrin targets a central process of cell motility machinery. Activity of de novo
synthesized sceptrin was indistinguishable from sceptrin puriﬁed from Agelas na-
kamurai, and the inhibitory activity was found to be, at least partially, due to scep-
trin’s capability to inhibit cell contractility. Additionally, sceptrin was found to
bind to monomeric actin, further suggesting a mechanism involving the actin cy-
toskeleton. Close analogues of sceptrin were synthesized, tested for their effect on
cell motility, and found to be either equimolar or less potent compared to the pa-
rental compound. Inadvertent cell motility is a key contributing factor in various hu-
man diseases, including cancer and chronic inﬂammation. Marine compounds iso-
lated from sponges have been proven to be an excellent source of metabolites
that show biological activities. Given the recently achieved total synthesis of scep-
trin in multigram quantities, sceptrin could prove to be an attractive lead mol-
ecule for further preclinical testing and development for therapeutic purposes, as
well as a useful research tool to elucidate the mechanisms involved in cell motility.
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eton functions in mammalian cells.
From a chemical standpoint, sceptrin provides a
unique challenge. In particular, its architecture includes
anasymmetricallyorientedtetrasubstitutedcyclobutane
inthecompanyofreactiveanddelicateheterocyclicspe-
cies, such as the 2-aminoimidazoles and oxidation
prone pyrroles. The ﬁrst total synthesis of sceptrin was
reported in 2004 (14), followed by an enantioselective
variant in 2005 (15), and a reﬁned route capable of de-
livering multigram quantities of the natural material was
reported in 2007 (16). These advances in chemical syn-
thesis overcome the common problem of product avail-
ability present for many natural compounds and have
set the stage for an extensive evaluation of sceptrin’s
potential in medicine.
In this work, we report the identiﬁcation of novel bio-
logical activity of sceptrin as inhibitor of cell motility.
Mechanistically, cell motility is effected through a com-
bination of alternating phases of cell protrusion and
contraction events. Polarized cells are able to induce la-
mellipodium protrusions at the front of the cell that at-
tachtotheunderlyingsubstrate.Oncethecellfrontisat-
tached to the underlying extracellular matrix, pulling
forces are generated and cell motility ensues by contrac-
tion of the cell body and retraction of the cell tail in the
rear (17, 18). It is known that actin stress ﬁbers are con-
tractile (19, 20) and play a central role in mediating cell
contractility during cell migration. Tightly regulated sig-
nalingpathwayscontrolactinstressﬁberpolymerization
and depolymerization during cell migration. Small GT-
Pase Rho and its target Rho-associated kinase (ROCK)
have been found to be key molecules in these regula-
tory pathways (21−24). Our studies here suggest that
sceptrin affects cell motility primarily by regulating cell
contractility. We further report that sceptrin binds mam-
malian monomeric actin, which could at least partially
explain sceptrin’s effects on cell contractility. Impor-
tantly, cell migration governs numerous physiological
and pathological cellular processes, including cancer
metastasis. A nontoxic inhibitor of cell motility, such as
sceptrin, could serve as an attractive lead molecule for
further development of potent cell motility inhibitors for
therapeutic use.
RESULTS AND DISCUSSION
Sceptrin Inhibits Cell Motility in HeLa Cells. The puta-
tive effect of sceptrin on cell motility was studied in hu-
man cervical cancer HeLa cell line. Cellomics Cell Motil-
ity reagent kit (see Methods) was used to analyze and
quantify cell motility changes. In this assay, exponen-
tially growing HeLa cells were seeded on plates that had
been covered with ﬂuorescence beads in complete
DMEM culture media supplemented with 10 ng mL1
of hepatocyte growth factor (HGF) to promote cell motil-
ity. Cells were treated with the indicated concentrations
of synthetic sceptrin (Figure 1, panel a) and allowed to
migrate for 24 h at 37 °C. As shown in Figure 1, panel a,
sceptrin inhibits HeLa cell motility in a dose-dependent
manner, as indicated by the shorter tracks produced by
sceptrin-treated cells. Quantitative analysis of cell motil-
ity was carried out by ImageJ software, which segments
the cell tracks and measures the track surface. Figure 1,
panel b shows average motility results of triplicates for
Figure 1. Sceptrin inhibits HGF-induced cell motility in HeLa cells. a)
HeLa cells were treated with sceptrin at indicated concentrations, and
cell motility was induced by hepatocyte growth factor (HGF) (10 ng
mL1). Cells were allowed to migrate for 24 h before ﬁxation. A repre-
sentative picture (10x objective) of one well for each condition is
shown. Three independent experiments done in triplicate for each con-
dition were carried out. b) ImageJ software was used to segment and
quantify cell tracks of the cell motility assay shown in panel a. Graph
represents surface on arbitrary units of the cell tracks. c) Effect of syn-
thetic and natural sceptrin (40 M) in cell motility is compared. HeLa
cells were induced to migrate as described for panel a. Each condition
was tested in triplicate. Cell tracks were analyzed as described for
panel b. d) Dose-dependent experiment was carried out in HeLa cells at
indicated sceptrin concentrations. Each condition was tested in tripli-
cate. Quantiﬁcation of cell motility was done as described in panel b.
Surface tracks were plotted, and a logarithmic trend line is shown.
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age track area (in pixels). It is important to note that
track segmentation includes the surface area covered
by cell bodies themselves. Thus, surface area of around
400 pixels consists of stationary cell bodies in this
analysis, and accordingly, surface area value of around
400 pixels indicates lack of cell movement.
Commercially available sceptrin that had been di-
rectly puriﬁed from the Agelas nakamurai sponge was
tested in parallel with synthetic sceptrin. As shown in
Figure 1, panel c, activities of the puriﬁed and synthetic
sceptrin were found to be indistinguishable. Synthetic
sceptrin demonstrated maximum inhibitory effect of cell
motility at a concentration of 50 M, with an IC50 value
of 15 M.
Sceptrin Inhibits Cell Motility in a Variety of Cancer
Cell Lines. We next tested whether the effect of scep-
trin on cell motility was cell-type or stimulus-dependent.
The MDA-MB-231 metastatic breast cancer cell line,
A549 lung cancer cell line and 3T3 mouse ﬁbroblasts
stably transfected with an active form of HGF receptor
(Tpr-Met 3T3 cells) were treated with sceptrin (40 M).
Prior to the addition of sceptrin, A549 cells were treated
with 10 ng mL1 of HGF to induce chemotactic cell mi-
gration. No stimulus was added on the MDA-MB-231
cells, which exhibit high baseline cellular motility (and
invasiveness).Tpr-Metcellsarealsohighlymotiledueto
activation of the HGF signaling pathway by the virtue of
Tpr-Met oncogene expression in the cells. As shown in
Figure 2, sceptrin demonstrated broad inhibitory effect
on cell motility in all the cell lines and conditions tested.
Sceptrin Does Not Prevent Cell Proliferation or Cell
Survival. A reduction in cell motility by sceptrin could
be secondary and caused by an induction of cell death
or due to impaired cell proliferation. Apoptosis and cell
proliferation assays were carried out next to study this
possibility. HeLa cells were seeded on 6-well plates at
low conﬂuence and allowed to grow in the presence or
absence of 40 M sceptrin. Cell number was measured
at indicated times while the cells were in an exponen-
tial growth phase. As shown in Figure 3, panel a, scep-
trin treatment had no effect on cell proliferation at any
Figure 2. Effect of sceptrin on cell motility in different can-
cer cell lines. ac) Indicated cells were seeded on top of
ﬂuorescence beads and treated with sceptrin (40 M).
Basal random motility was measured for cells in panels a
and b. Motility was stimulated by hepatocyte growth fac-
tor (HGF) (10 ng mL1) in panel c. Cells were ﬁxed after
24 h, a picture of each well (all the conditions were as-
sayed in triplicate) was taken, and the surface of the cell
tracks was segmented and quantiﬁed.
Figure 3. Effect of sceptrin on apoptosis and cell prolifera-
tion. a) Effect of sceptrin on cell proliferation was tested in
HeLa cells, which were seeded at low density and treated
with vehicle, sceptrin (40 M), or positive control aphidi-
colin (5 nM). Proliferation was quantiﬁed by cell counting
at indicated times. b) Putative induction of apoptosis by
sceptrin was assayed in HeLa cells, which were treated
with sceptrin at indicated concentrations or with the posi-
tive control staurosporine (5 nM) for 24 h. Apoptosis was
quantiﬁed by immunochemical determination of histone-
complexed DNA fragments in a microplate well.
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aphidicolin readily inhibited cell proliferation. To mea-
sure apoptosis, exponentially growing HeLa cells were
treated by different concentrations of sceptrin, as indi-
cated in Figure 3, panel b. A Cell Death Detection ELISA
kit (see Methods) was used to quantify apoptosis. As a
positive control, cells were treated with 5 nM staurospo-
rine. No apoptosis was observed at any tested concen-
trations of sceptrin, including twice (100 M) the con-
centration of sceptrin that yields maximum inhibition of
cell motility. These data conﬁrm previous reports that
show no toxicity by sceptrin in mice or monkey liver cells
(6, 12) and demonstrate that sceptrin did not exhibit
any cytotoxic activity in the cell lines studied here. Since
it was isolated by Walker and co-workers in 1981, scep-
trinhasbeentestedandfoundtoexhibitavarietyofbio-
logical activities including anti-microbial and anti-
muscarinic activities, to inhibit depolarization-induced
cellular calcium elevation, and to inhibit somatostatin
and vasoactive intestinal polypeptide (VIP) activities (6,
8, 9, 11). Here, we report a novel biological activity of
sceptrin as inhibitor of cell migration. The inhibitory ef-
fect of sceptrin on cell motility is not restricted to a spe-
ciﬁc tissue or cell type, as we found sceptrin to be active
in different cell lines, including human breast and lung
cancer cell lines, as well as in transformed mouse ﬁbro-
blast cells.
Effect of Various Sceptrin Analogues on Cell
Motility. To identify which chemical group(s) of scep-
trin are important for the observed inhibition of motil-
ity, various sceptrin derivatives were synthesized.
Figure 4 depicts the chemical structure of all tested
sceptrin-derived compounds. On the basis of the fact
that differences in the way sceptrin chemically reacts as
a function of salt type have been observed (16), three
different salts of sceptrin (chloride, acetate, and triﬂu-
oroacetate) were examined to assess the possible (al-
though unlikely) unspeciﬁc effect of the anions in the ef-
fect of sceptrin on cell motility. As shown in Figure 5,
none of the salts showed signiﬁcant differences in the
motilityinhibitionwhentestedinHGF-treatedHeLacells.
None of the analogues tested appeared to be superior
compared to the parent sceptrin compound. In contrast,
debromosceptrin and, more signiﬁcantly, the two forms
of the nakamuric acid compounds demonstrated re-
duced effect on cell motility compared to the parent
compound. Thus, these studies suggest a critical role
Figure 4. Structure of synthesized sceptrin-derived compounds. Five dif-
ferent sceptrin-derived compounds were synthesized to test their abil-
ity to block cell motility. In summary, extra bromide groups were added
or original bromides were removed from the pyrrole group of sceptrin
to generate the bromo, dibromo, or debromo compounds. Nakamuric
compounds lack one of the aminoimidazole groups of sceptrin. On the
oxysceptrin compound an oxygen is added to one of the aminoimida-
zole groups.
Figure 5. Effect on cell motility of the various sceptrin-
derived compounds. HeLa cells were allowed to migrate in
the presence of hepatocyte growth factor (HGF) (10 ng
mL1). As indicated cells were treated with sceptrin or
sceptrin-derivatives (40 M) for 24 h as described above.
Control cells were treated with vehicle (H2O). Cell motility
was quantiﬁed as described in Methods.
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the nakamuric acid compounds) in the inhibition of cell
motility.
SceptrinDoesNotBlockLamellipodiaFormation.Mo-
tility is a complex process that involves several differ-
ent mechanisms and steps. In broad terms, the various
steps of cell motility include extension of the plasma
membrane and formation of lamellipodia in the leading
edge of the motile cell, generation of contractility forces
that propels the cell forward, and ﬁnally, detachment of
the rear tail to allow cell movement. Confocal video-
microscopy analysis was performed to evaluate the ef-
fect of sceptrin on these various steps of cell motility.
GFP-Actin expressing HeLa cells that had been treated
withHGF(10ngmL1)orGFP-Actinexpressinguntreated
MDA-MB-231 cells were allowed to exponentially grow
for 24 h on 4-well LabTek chambers that had been
coated with ﬁbronectin, followed by automated
temperature-controlled time-lapse confocal microscopy
(see Methods for details). A still image of live cells
treated or untreated with sceptrin was taken every 2 min
up to 3 h. Images of MDA-MB-231 cells were taken us-
ing a 20x objective to capture a large number of cells for
analysis. A 40x objective was used for HeLa cells to ana-
lyze individual cell dynamics in more detail. Movies
were mounted using the NIH ImageJ software. Figure 6
shows an RGB composite of the cell image, in which
red color indicates time 0, green indicates the 1 h time-
point, blue the 2 h time-point, and white the 3 h time-
point. Actual composite videos can be found in the on-
line Supporting Information. Time-lapse results show
that sceptrin-treated cells demonstrate actin dynamics
on the cell membrane, including lamellipodia formation,
indistinguishable from those observed in nontreated
cells. Thus, it appears that sceptrin has no effect on cor-
tical actin polymerization required in the initial exten-
sion of the plasma membrane during cell motility. Con-
ﬁrming our previous data, sceptrin-treated cells
demonstrated reduced cell motility compared to un-
treated cells in the time-lapse study. As shown in the
composite movies (see online Supporting Information),
initial protrusion of the cell body appears to occur nor-
mally in sceptrin-treated cells. However, directional
movement of the cell fails to take place, resulting in sub-
sequent retraction of the protrused lamellipodia. Thus,
theseresultssuggestthatsceptrinmightinhibitthegen-
eration of the contractile forces in the cell that are re-
quired for movement of the cell body, after the initial la-
mellipodia formation has taken place.
Inhibition of Cell Contractility by Sceptrin. To study
the possibility that sceptrin affects cell contractility to in-
hibit cell migration, a contractility assay known as clot
retraction assay was performed (see Methods). Brieﬂy,
CHO cells stably transfected with human IIb3 integrin
(CHO) were mixed with human plasma, thrombin,
and CaCl2 in a Sigmacote-treated glass tube. Formed
clot was allowed to retract for 2 h before pictures were
taken. 2D images of the retracted clots were segmented
and quantiﬁed using ImageJ software. As shown in
Figure 7, panel b, pretreatment of CHOIIb3 cells with
sceptrin signiﬁcantly reduced clot retraction when com-
Figure 6. Time-lapse confocal video microscopy of cells
treated with sceptrin. a) Effect of sceptrin on cell motility
dynamics was tested on MDA-MB-231 cells transiently
transfected with GFP-actin construct. Cells that had been
seeded on ﬁbronectin-coated LabTek chambers were pic-
tured (20x objective) every 2 min up to 3 h. Panel a shows
an RGB composite still image taken at time 0, 1, 2, and
3 h, where red represents 0 h, green 1 h, blue2ha n d
white 3 h. Actual movies can be seen in online Supporting
Information. b) Effect of sceptrin on HeLa cells was as-
sayed as described for panel a. HeLa cells were induced to
migrate by addition of hepatocyte growth factor (HGF) (10
ng mL1). A 40x objective was used to take the pictures in
this case.
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XI inhibitor was used, and as expected, calpain inhibi-
tor completely blocked cell contractility. Thus, these re-
sults provide the ﬁrst insights to the molecular mecha-
nisms as to how sceptrin might inhibit cell motility, that
is, by inhibiting cell contractility. To extend these stud-
ies further, we tested the possibility that sceptrin could
directly bind actin. By using isothermal titration calorim-
etry, we show that sceptrin binds to monomeric actin
with an equilibrium dissociation constant (Kd) of 19.2
 0.2 M (Figure 7, panel c). Thus, these ﬁndings are
consistent with the results obtained by Rodriguez and
co-workers demonstrating that sceptrin interacts with
thebacterialMreBprotein,whichisconsideredtobethe
actin homologue in bacteria (13).
Other potential mechanisms how sceptrin affect cell
contractility and cell motility beyond its binding to actin
remain to be determined. It is known that the small GT-
Pase Rho plays a central role in the regulation of cell
contractility by controlling actin stress ﬁber formation
(23−25); for a recent review see ref 26. In our unpub-
lished data, sceptrin had no effect on the levels of ac-
tive, GTP-bound Rho in cells. Whether sceptrin regulates
downstream effectors of Rho, such as ROCK and mDIA1
(21, 22, 27), remains to be tested. Finally, sceptrin’s ef-
fect on cell motility could be mediated by its anti-
muscarinic activity, as muscarine receptors have been
implicated in migration in keratinocytes (28, 29). In our
unpublished studies, however, neither muscarine (a
muscarinic agonist) or atropine (a muscarinic antago-
nist) demonstrated any effect on cell motility of the cell
lines used in this study, nor did they inﬂuence the capa-
bility of sceptrin to inhibit cell migration.
Marine organisms have been found to be a very pro-
ductive source of metabolites with clinically interesting
properties (1). Two marine products, namely, Ziconotide
(Prialt; Elan Pharmaceuticals) in 2004 and Trabectedin
(Yondelis; PharmaMar) in 2007 have been approved for
clinical use by the FDA and European Union, respec-
tively (30). Development of marine products for pharma-
ceutical use has frequently been prevented by the
scarceness of the compounds from the natural sources
(1). Additionally, complete chemical synthesis of these
molecules can be very complicated involving may reac-
tion steps, making synthesis unappealing for industrial
use. Importantly, the total synthesis of sceptrin was ﬁrst
resolved in 2004 (14), and in 2007 Dr. Baran’s group
discoveredareﬁnedroutecapableofyieldingmultigram
quantities of the product (16). Thus, the newly found
biological activity of sceptrin in inhibiting cell motility,
combined with the availability of synthetic sceptrin in
multigramquantities,makessceptrinaninterestingcan-
Figure 7. Inhibition of cell contractility and actin binding
by sceptrin. a) Cell contractility was assayed using the clot
retraction assay. CHOIIb3 cells treated with vehicle,
sceptrin (40 M), or 10 M Calpain inhibitor XI (positive
control) were mixed with human serum, thrombin (2 U
mL1), and CaCl2 (5 mM). Clot was allowed to retract for
2 h, and still images were taken. All conditions were
tested in triplicate and assayed in three independent ex-
periments. Panel a shows a representative picture of each
condition. b) 2D size of clots was segmented and quanti-
ﬁed using the NIH ImageJ software. c) Isothermal titration
calorimetry (ITC) binding curve after subtraction of the
heat associated with sceptrin dilution. Kd  19.4 
0.2 M for sceptrin binding to G-actin is an average ob-
tained from two independent measurements.
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eases in which inadvertent cell motility is a key contrib-
uting factor, such as cancer and chronic inﬂammation.
Here, sceptrin was found to be capable of inhibiting
both chemotactic HeLa cell migration induced by HGF
and haptotactic cell motility of unstimulated MDA-MB-
231 cells on ﬁbronectin. Further, the inhibitory effect is
not stimulus-dependent. These data suggest that scep-
trin likely affects a signaling event common to all (or, a
number of) motogenic pathways or exerts its effects
through the cellular contractility machinery (e.g., actin
stress ﬁbers) directly. Given the lack of toxicity by scep-
trin,andtherecentlyachievedtotalsynthesisofsceptrin
inmultigramquantities,sceptrincouldprovetobeanat-
tractive lead molecule for further preclinical testing and
development for therapeutic purposes, as well as a use-
ful research tool to elucidate the mechanisms involved
in cell motility.
METHODS
Cell Culture and Transfections. HeLa, MDA-MB-231, and A549
cells were obtained from American Type Culture Collection
(ATCC). NIH 3T3 cells stably transfected to express the Tpr-Met
oncoprotein were generously provided by Dr. George Vande
Woude. CHO cells expressing the IIb3 integrin were gener-
ously provided by Dr. Sanford Shattil. The cells were cultured in
Dulbecco’s modiﬁed Eagle’s medium (DMEM) supplemented
with 10% fetal calf serum (FCS), 2 mM glutamine, 100 U mL1
streptomycin, and 100 gm L 1 penicillin (Irvine Scientiﬁc). Cell
transfections were performed using Lipofectamine and Plus Re-
agent (Invitrogen) following the manufacturer’s instructions.
Plasmids and Other Reagents. GFP-Actin construct was pur-
chased from BD Biosciences. HGF was purchased from R&D Sys-
tems Inc. Natural sceptrin isolated from the sponge Agelas na-
kamurai was bought from A. G. Scientiﬁc, Inc. Calpain XI
inhibitor was purchased from Calbiochem. Synthetic sceptrin,
bromosceptrin, dibromosceptrin, debromosceptrin, oxysceptrin,
and nakamuric acid and its methyl ester were synthesized as de-
scribed in ref 16. Lyophilized human plasma, thrombin, and Sig-
macote were purchased from Sigma. Aphidicolin was bought
from Sigma. Staurosporine was purchased from Calbiochem.
Cell Migration Assays. Motility assays were performed by us-
ing the Cell Motility HitKit (Cellomics). In this assay, ﬁve hun-
dred cells per well were plated on 96-well dishes coated with
blue ﬂuorescence beads and cultured in complete medium for
24 h in the absence or presence of HGF (10 ng mL1) as indi-
cated in ﬁgure legends. Cell tracks generated upon cell move-
ment were analyzed by using a ﬂuorescence microscopy at 10x
magniﬁcation. Using the freeware NIH ImageJ software, pictures
were converted to binary mode, cell tracks were segmented,
and the track surface was quantiﬁed.
Cell Proliferation Assay. HeLa cells were seeded in 6-well
dishes at low conﬂuence (30,000 cells well1), treated with ve-
hicle (H2O) or 40 M of sceptrin and allowed to grow in complete
medium up to 96 h. Medium containing fresh sceptrin or ve-
hicle were replaced every 24 h. Cells were manually counted in
a Neubauer chamber at 24, 48, 72, and 96 h.
Cell Death Assay. HeLa cells seeded in 6-well dishes at 50%
conﬂuence were treated with 10, 50, or 100 M sceptrin, ve-
hicle (H2O), or 5 nM staurosporine as positive control for 24 h.
After treatment, cell death was analyzed by quantitative detec-
tion of cytoplasmic histone-associated DNA fragments using the
Cell Death Detection ELISA kit (Roche). Manufacturer’s pro-
vided instructions were followed without any modiﬁcation.
Time-Lapse Confocal Microscopy. HeLa or MDA-MB-231 cells
transiently transfected to express the GFP-actin fusion protein
were seeded on 4-well LabTek chambers that had been coated
with 10 gm L 1 of ﬁbronectin. When indicated, cells were
treated with 40 M of sceptrin for 3 h prior to placing the cham-
bers under the microscope. Cell motility in HeLa cells was stimu-
lated with HGF (10 ng mL1), whereas MDA-MB-231 cells were
allowed to freely migrate in the complete culture medium with-
out addition of any chemotactic agent. Chambers with the living
cells were placed under an automated, temperature-controlled
Olympus confocal microscope at 37 °C. A still image was taken
every 2 min up to 3 h. Time-lapse movies and RGB composite im-
ages were mounted using the freeware NIH Image software
(movies can be seen online in Supporting Information).
Clot Retraction Assay. A 400 L sample of CHOIIb3 cells (4
 106 mL1), in complete DMEM in the presence or absence of
sceptrin (40 ) or calpain XI inhibitor (10 M), was mixed with
100 L of human plasma,2Um L 1 thrombin, and 5 mM CaCl2
in a partially Sigmacote-treated glass cuvette. The clots were al-
lowed to retract for2ha t3 7° Ca n dwere photographed. The
two-dimensional areas of retracted clots in the photographs
were quantiﬁed using the NIH ImageJ software and the results
were expressed as clot size.
Isothermal Titration Calorimetry (ITC). ITC was carried out on
an ITC200 calorimeter (Microcal). Aliquots (2 L) of 3.0 mM
sceptrin in water were injected into the cell containing 65 mM
monomeric (G) actin in G-actin buffer (5 mM Tris pH 8.3, 0.3 M
CaCl2, 0.1 mM NaN3, 0.1 mM EDTA, 0.5 mM DTT, 0.24 mM ATP,
and 1 gm L 1 Leupeptin). G-actin was a generous gift from Drs.
Robert Jeng and Dorit Hanein and was puriﬁed as described in
ref 31. Equilibrium association constant (Ka) was obtained by ﬁt-
ting experimental data to “One set of sites” binding model us-
ing the Origin 7 software package (Microcal). Equilibrium disso-
ciation constant (Kd) was calculated as Kd  1/Ka.
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